An Act to promote transparency and cost control of pharmaceutical drug prices
By Mr. Montigny, a petition (accompanied by bill, Senate, No. 1048) of Mark C. Montigny, Jason M. Lewis, James B. Eldridge, Michael O. Moore and other members of the General Court for legislation to promote transparency and cost control of pharmaceutical drug prices. Mental Health and Substance Abuse.
Bill History
| Date | Branch | Action |
|---|---|---|
| 4/15/2015 | Senate | Referred to the committee on Mental Health and Substance Abuse |
| 4/15/2015 | House | House concurred |
| 9/10/2015 | Senate | Discharged to the committee on Health Care Financing |
| 9/14/2015 | House | House concurred |
| 2/12/2016 | Joint |
|
| 3/16/2016 | Joint | Hearing canceled – new hearing TBD |
| 4/29/2016 | Senate | Reporting date extended to Wednesday June 1, 2016, pending concurrence |
| 5/2/2016 | House | Adopted, in concurrence |
| 6/2/2016 | Senate | Accompanied a study order, see S2307 |
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.